Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
Title:
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
Author:
Felip, E. Rojas, C.I. Schenker, M. Kowalski, D.M. Casarini, I.A. Csöszi, T. Şendur, M.A.N. Martins, J. Calles Blanco, A. Wang, C.-C. Wang, M. Ramirez Fallas, R.A.L. Yoshioka, H. Nair, S. Song, X. Deng, X. Lala, M. Eiras, R. Takahashi, T.
Appeared in:
Annals of oncology
Paging:
Volume 36 () nr. 7 pages 775-785
Year:
2025
Contents:
Publisher:
Merck & Co., Inc., Rahway, NJ, USA and its affiliates, The Author(s)